Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Other Working Capital Changes (2020 - 2025)

Foghorn Therapeutics has reported Other Working Capital Changes over the past 6 years, most recently at -$21.3 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$21.3 million for Q4 2025, down 554.55% from a year ago — trailing twelve months through Dec 2025 was -$47.9 million (down 3536.9% YoY), and the annual figure for FY2025 was -$2.8 million, down 114.65%.
  • Other Working Capital Changes for Q4 2025 was -$21.3 million at Foghorn Therapeutics, down from -$17.0 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for FHTX hit a ceiling of $20.9 million in Q4 2023 and a floor of -$27.8 million in Q3 2023.
  • Median Other Working Capital Changes over the past 5 years was -$1.8 million (2022), compared with a mean of -$3.5 million.
  • Biggest five-year swings in Other Working Capital Changes: skyrocketed 1064.14% in 2021 and later crashed 5582.35% in 2022.
  • Foghorn Therapeutics' Other Working Capital Changes stood at $2.4 million in 2021, then plummeted by 272.85% to -$4.2 million in 2022, then skyrocketed by 598.97% to $20.9 million in 2023, then plummeted by 77.55% to $4.7 million in 2024, then plummeted by 554.55% to -$21.3 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$21.3 million (Q4 2025), -$17.0 million (Q3 2025), and -$8.5 million (Q2 2025) per Business Quant data.